Your browser doesn't support javascript.
COVID-19 as a Risk Factor for Alzheimer's Disease.
Golzari-Sorkheh, Mahdieh; Weaver, Donald F; Reed, Mark A.
  • Golzari-Sorkheh M; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Weaver DF; Krembil Research Institute, University Health Network, Toronto, ON, Canada.
  • Reed MA; Department of Chemistry, University of Toronto, Toronto, ON, Canada.
J Alzheimers Dis ; 2022 Oct 26.
Article in English | MEDLINE | ID: covidwho-2230436
ABSTRACT
Severe acute respiratory disease coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although a primarily respiratory disease, recent reports indicate that it also affects the central nervous system (CNS). Over 25% of COVID-19 patients report neurological symptoms such as memory loss, anosmia, hyposmia, confusion, and headaches. The neurological outcomes may be a result of viral entry into the CNS and/or resulting neuroinflammation, both of which underlie an elevated risk for Alzheimer's disease (AD). Herein, we ask Is COVID-19 a risk factor for AD? To answer, we identify the literature and review mechanisms by which COVID-19-mediated neuroinflammation can contribute to the development of AD, evaluate the effects of acute versus chronic phases of infection, and lastly, discuss potential therapeutics to address the rising rates of COVID-19 neurological sequelae.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Long Covid Language: English Journal subject: Geriatrics / Neurology Year: 2022 Document Type: Article Affiliation country: JAD-220800

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Long Covid Language: English Journal subject: Geriatrics / Neurology Year: 2022 Document Type: Article Affiliation country: JAD-220800